Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-07-02
1998-12-22
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 8, 514 12, 514885, 514934, 4241881, 4242051, 530324, 530397, 530398, 530399, 530828, A61K 3800, A61K 3921, C07K 100
Patent
active
058519971
ABSTRACT:
Prophylaxis against viral infections, as well as treatment for individuals infected with a virus, can be achieved through the administration of human chorionic gonadotropin (HCG). Exemplary of the viral infections that are amenable to the use of HCG in this regard include those caused by HIV-1, Kaposi's sarcoma herpes virus, molluscipoxvirus and cytomegalovirus. In addition, HCG can be used as a neonatal immune booster via administration to a baby at delivery and, optionally, for the first several months of life, until the infantile immune system matures, in order to prevent HIV transmission and control any low-level viremia, as well as to protect against various other viruses, such as herpes viruses and oncogenic viruses.
REFERENCES:
patent: 4692332 (1987-09-01), McMichael
patent: 4877610 (1989-10-01), McMichael
patent: 4880626 (1989-11-01), McMichael
patent: 4966753 (1990-10-01), McMichael
patent: 4970071 (1990-11-01), McMichael
Cohen Is a New Virus the Cause of KS? Science, 266:1803-4 (1994).
Chang Identification of Herpesvirus-Like DNA Sequences in AIDS-Associated Kaposi's Sarcoma Science, 266:1865-9 (1994).
Rosenthal Maladie de Kaposi et hormones sexuelles: a propos d'une observation, revue de la litterature Rev Med Interne 15:186-9 (1994).
Ambroziak Herpes-Like Sequences in HIV-Infected and Uninfected Kaposi's Sarcoma Patients Science 268:582-3 (1995).
Lunardi-Iskandar Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone Nature 375:64-8 (1995).
Ritter Pregnancy Hormone May Treat AIDS-Related Condition, Report Suggests (1995) Associated Press.
Monfardini Treatment of acquired immunodeficiency syndrome (AIDS)-related cancer Cancer Treatment Reviews 20:149-172 (1994).
Lilenbaum Systemic Treatment of Kaposi's sarcoma: current status and future directions AIDS 8:141-151 (1994).
10th International AIDS meeting, Yokohama, Japan (1994).
HCG and Kaposi's Sarcoma Pl Perspectives . . . Nov. 1994.
Stein Aids Related Kaposi's Sarcoma: A Review, Israel Journal of Medical Sciences, 30:298-305 (1994).
Harris Human Chorionic Gonadotropin Hormone Is Antiviral Medical Hypotheses 47:71-72 (1996).
Cohen Controversy: Is KS Really Caused By New Herpesvirsu? (1995) Science 268:1847-8.
Bourinbaiar et al, FEBS. LETS, vol. 309, No. 1, pp. 82-84, Aug. 1992.
Gold, Treatment Science, vol. 8, No. 7, pp. 1-2, 1994.
"New Directions Needed for AID Research," Computer Dialog, PHIND (Archival), Aug. 19, 1994.
Sandstrom et al., Review Articles in Drugs, vol. 34, pp. 373-390, 1987.
Haynes, Science, vol. 260, pp. 1279-1286, 28 May 1993.
Fox, Bio/Technology, vol. 12, p. 128, 12 Feb. 1994.
Brown, The Washington Post, Jun. 10, 1993.
Mohamed Abdel A.
Tsang Cecilia J.
LandOfFree
Use of human chorionic gonadotropin as an immune-potentiating an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of human chorionic gonadotropin as an immune-potentiating an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of human chorionic gonadotropin as an immune-potentiating an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2047773